
**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION**

WASHINGTON, D.C. 20549

FORM 8-K

**CURRENT REPORT
Pursuant to Section 13 or 15(d)
of The Securities Exchange Act of 1934**

Date of Report (Date of earliest event reported): **December 6, 2017**

Editas Medicine, Inc.

(Exact Name of Registrant as Specified in its Charter)

Delaware
(State or Other Jurisdiction of
Incorporation)

001-37687
(Commission File Number)

46-4097528
(IRS Employer Identification No.)

11 Hurley Street
Cambridge, Massachusetts
(Address of Principal Executive Offices)

02141
(Zip Code)

Registrant's telephone number, including area code: **(617) 401-9000**

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Item 2.03. Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant.

As previously reported, on December 16, 2016, Editas Medicine, Inc. (the “Company”) entered into a Cpf1 License Agreement (the “Cpf1 Agreement”), by and between the Company and The Broad Institute, Inc. (“Broad”), for specified patent rights related primarily to Cpf1 compositions of matter and their use for gene editing. Pursuant to the Cpf1 Agreement, Broad, on behalf of itself, President and Fellows of Harvard College (“Harvard”), the Massachusetts Institute of Technology (“MIT”), Wageningen University, and the University of Tokyo granted the Company a license to those specified patent rights, subject to certain limitations and retained rights, in exchange for certain royalty, success, and milestone payments. Concurrently with entering into the Cpf1 Agreement, the Company and Broad entered into a Cas9-II License Agreement (the “Cas9-II Agreement”) for specified patent rights related primarily to certain Cas9 compositions of matter and their use for gene editing. Pursuant to the Cas9-II Agreement, Broad, on behalf of itself, MIT, Harvard, and the University of Iowa Research Foundation, granted the Company a license to those specified patent rights, subject to certain limitations and retained rights, in exchange for certain royalty, success, and milestone payments.

On December 6, 2017 (the “Trigger Date”) a success payment under each of the Cpf1 Agreement and the Cas9-II Agreement became due upon the market capitalization of the Company’s common stock reaching \$1,000,000,000 (as calculated under each of the Cpf1 Agreement and the Cas9-II Agreement). The total payment due under the Cpf1 Agreement is \$5,000,000 (the “Cpf1 Success Payment”) and the total payment due under the Cas9-II Agreement is \$2,500,000 (together with the Cpf1 Success Payment, the “Success Payments”). The Success Payments must be paid no later than 12 days after the Trigger Date and will be paid by the issuance of promissory notes (the “Notes”) to Broad (or its designees). The Notes shall bear interest at a rate of 4.8% per annum. Principal and interest on the Notes will be payable 150 days following the issuance date of the Notes, and the Company may prepay the Notes at any time. The Notes will be convertible, at the option of the Company, into common stock of the Company subject to certain conditions. In the event of a change of control of the Company or a Company sale, the Company is required to pay all remaining principal and accrued interest on the Notes in cash within a specified period following such event. Under the terms of the Notes, the entire unpaid principal and interest of the Notes shall become immediately due and payable upon a payment default or bankruptcy- and insolvency-related defaults.

Descriptions of the other material terms of the Cpf1 Agreement and the Cas9-II Agreement are hereby incorporated by reference to the Company’s Current Report on Form 8-K filed with the Securities and Exchange Commission on December 21, 2016.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

EDITAS MEDICINE, INC.

Date: December 12, 2017

By: /s/ Andrew A. F. Hack

Andrew A. F. Hack

Chief Financial Officer
